uPAR和HER2在乳腺浸润性导管癌中的表达及其相关性

Clinical Significance and Correlation of uPAR and HER2 Overexpression in Infiltrating Ductal Breast Cancer

目的:探讨乳腺浸润性导管癌尿激酶型纤溶酶激活物受体(uPAR)和人类表皮生长因子2(HER2)表达、相关性及临床意义。方法:采用免疫组织化学技术检测15例正常乳腺组织和60例原发性乳腺浸润性导管癌中尿激酶型纤溶酶激活物(uPA)、uPAR和HER2基因的表达。结果:乳腺浸润性导管癌组织uPA和uPAR蛋白表达的总阳性率分别为60.00%和63.33%,而支持组织无表达,uPAR的阳性表达与乳腺癌转移淋巴结个数有关;HER2表达总阳性率为67%,有淋巴结转移者其阳性率(65.22%)明显高于无淋巴结转移者(35.14%)(P<0.05);与uPAR阴性表达的癌组织相比,uPAR阳性的癌组织中HER2表达阳性率显著升高(84.21%±36.36%,P<0.05),uPAR与HER2之间的表达高度相关。结论:uPAR和HER2蛋白在乳腺浸润性导管癌中高度表达,且密切相关;HER2过度表达与乳腺浸润性导管癌淋巴结转移有关,而uPAR表达与转移的淋巴结个数有关。

Objective： To investigate the significances and Correlation of uPAR and HER2 over-expression in the infiltrating ductal breast carcinoma. Methods： Immunohistochemical technique was used to determine the expressions of uPA, uPAR and HER2 in 15 cases of normal breast and 60 cases of infiltrating ductal breast cancer. Results： The positive rate of uPA and uPAR protein expression in primary breast carcinoma was 60.00% and 63.33% respectively. The uPAR positive expression was positively correlated to the number of the lymphatic metastasis in breast carcinoma （P〈0.05）. The positive rate of HER2 protein expression in breast carcinoma was 67.00%, of which the positive rate with lymphatic metastasis was significantly higher than that without lymphatic metastasis （65.22% versus 35.14%, P〈0. 05）. In the uPAR positive breast cancer, the positive rate of HER2 expression （84.21%） was higher than that in the breast cancers without uPAR expression. There was significant correlation between uPAR and HER2. Conclusion： Overexpressions of uPAR and HER2 protein occurred in primary breast carcinoma with a close correlation between each other. Expressions of HER-2 and uPAR in infiltrating ductal breast carcinoma are useful for predicting lymphatic metastasis of breast carcinoma.